Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities

To the Editor Hall et al¹ describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA in the Phase 3 Study of Aducanumab in Early Alzheimer’s Disease (EMERGE and ENGAGE) trials,² we believe this work is of particular interest as it points out ARIA as a timely research and clinical priority, prompting the urgent need to define standardized guidelines for the treatment and follow-up monitoring of such side events.